Join our Webinar   Date: Monday, November 13th  Time: 12:00 PM EST / 9:00 AM PST

Placebo Response in Clinical Trials: Approaches to Mitigation

Industry Trends

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus et sapien eget nunc ultrices malesuada. Suspendisse et venenatis nisl, in scelerisque elit. Etiam fermentum, enim at tempor egestas, ipsum nisi efficitur risus, id commodo lectus nisl sit amet enim. Sed ut dictum eros, nec fermentum odio. Curabitur varius diam non felis ultricies, vel accumsan enim rhoncus. Nullam egestas, lorem vitae fringilla pharetra, nisl est molestie mauris, quis porta elit nisi sit amet justo. Nulla rutrum tempor orci nec cursus. Integer consectetur tristique ante quis suscipit. Nullam et justo faucibus, congue mi non, malesuada augue. Morbi quis odio imperdiet, aliquam dolor id, malesuada nulla. Integer sit amet ultricies lorem.

Pellentesque tincidunt dui orci, non faucibus felis iaculis eu. Proin sit amet interdum quam. Suspendisse pulvinar libero vitae magna posuere varius. Nullam faucibus a lacus facilisis molestie. Mauris ac est laoreet, posuere sapien quis, posuere nulla. Cras cursus tristique nisi vel cursus. Aenean neque felis, placerat ut quam vitae, auctor sagittis dui. Duis quis congue risus. Duis a laoreet quam, vitae interdum turpis. Donec facilisis condimentum ultrices. Pellentesque tristique justo id vehicula vestibulum. Register for this webinar to become part of the conversation and learn how to increase the chances of trial success in an uncertain world.


Sofija Jovic, PhD, MBA
Business Transformation Advisor


President, Analgesic Solutions
Adjunct Assistant Professor of Anesthesia
Tufts University School of Medicine


Mark G. A.Opler, PhD, MPH
Chief Research Officer

Join the conversation on Twitter by using the hashtag #placeboresponse, and follow us on LinkedIn for webinar updates!

PANSS and CGI-S: Ten Years Later

Analysis provides additional evidence of substantial agreement between PANSS total score and CGI-S rating; brings into question the additional value of CGI-S administration in view of its limitations including expectancy...

Read More

U. of Chicago Booth School Presents Distinguished Alumni Award to Amy Ellis

Prestigious Award Recognizes Outstanding Professional Achievement

Hamilton, NJ (May 2, 2017) — MedAvante, Inc., the leading global clinical data services company dedicated to maximizing signal detection in clinical trials, announced that Amy Ellis, president and co-founder, has been selected to receive the Distinguished Alumni Award (DAA) from the University of Chicago Booth School of Business.

Araclon Biotech Selects MedAvante Virgil Platform for Phase 2 Alzheimer’s Trial

Shared Goal Is Improving Signal Detection and Data Quality through Standardization

Zaragoza, Spain and Hamilton NJ, USA (March 30, 2017) — Araclon Biotech, a Grifols company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, and MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, today announced that Araclon Biotech has selected MedAvante’s groundbreaking Virgil® Investigative Study Platform for its upcoming Phase 2 trial in prodromal or very mild Alzheimer’s disease (AD).

MedAvante Names Ropacki Head of Research and Development

Accomplished Clinical Scientist Will Accelerate Company’s Growth

Hamilton, NJ (February 22, 2017) — MedAvante, Inc., the leading global clinical data services company dedicated to maximizing signal detection in clinical trials, announced that Michael T. Ropacki, PhD, has been appointed Vice President, Research and Development to lead the company’s continued expansion of clinical science and signal detection capabilities.